Bucillamine: A Potent Thiol Donor with Multiple Clinical Applications

Overview of attention for article published in Cardiovascular Drug Reviews, June 2006

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
One of the highest-scoring outputs from this source (#1 of 177)
High Attention Score compared to outputs of the same age (99th percentile)
High Attention Score compared to outputs of the same age and source (98th percentile)

Mentioned by

news: 11 news outlets
twitter: 60 X users
patent: 6 patents

wikipedia: 2 Wikipedia pages
reddit: 17 Redditors

Readers on

mendeley: 29 Mendeley

So far, Altmetric has seen 11 news stories from 11 outlets.

Revive Therapeutics Provides Update on Research Study Evaluating Bucillamine for Nerve Agent Exposure and Expansion into Viral Infections

Morning Star, 28 Aug 2024

TORONTO, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKF…

News story from Finanz Nachrichten on Wednesday 28 August 2024

Finanz Nachrichten, 28 Aug 2024

Revive Therapeutics Provides Update on Research Study Evaluating Bucillamine for Nerve Agent Exposure and Expansion into Viral Infections

ADFN, 28 Aug 2024

Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences…

Revive Therapeutics Provides Update on Research Study Evaluating Bucillamine for Nerve Agent Exposure and Expansion into Viral Infections

Stockwatch, 28 Aug 2024

TORONTO, Aug. 28, 2024 (GLOBE NEWSWIRE) Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT…

This page shows the most recent news stories that mention this research output. Click here to find out how to access more activity, including 7 additional news stories.